Inceptor Bio, a US-based biotechnology company advancing cell therapies for difficult-to-treat cancers, announced on Monday that it has named Dr Matthias Schroff as its new CEO.
The new CEO is also joining the board of directors. He succeeds Shailesh Maingi, who will remain as executive chairman.
Dr Schroff has extensive biopharmaceutical leadership experience. He has served as chief executive officer of Exicure, chief executive officer of Vaximm AG and held several positions on management levels at Mologen, ultimately rising to chief executive officer.
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business
Insmed receives highest ranking in Science's 2024 Top Employers Survey
OncoZenge partners with Pharmanovia for exclusive BupiZenge commercialization in EMENA regions